A comprehensive analysis of federal survey data reveals that while GLP-1 drugs improve blood sugar and weight, they do not produce significant changes in mental health, employment, or marriage among adults with diabetes, challenging assumptions about their broader social benefits.
An economic analysis of federal survey data suggests that GLP-1 medicines may improve blood sugar and body weight without producing measurable changes in several wider life outcomes for adults with diabetes, including mental health, self-rated health, work status or marriage.
The findings come from a National Bureau of Economic Research working paper by University of Chicago economist Robert Kaestner and co-author Cuiping Schiman, which drew on the Medical Expenditure Panel Survey covering 2012 through 2023. Rather than comparing people who used GLP-1 drugs with those who did not, the researchers tracked the same individuals over time to see whether their circumstances changed after treatment began. The study covered 4,284 observations for women and 3,672 for men.
That approach produced a largely flat result. On the measures the authors examined, GLP-1 use was not linked to meaningful shifts in depression screens, psychological distress, employment or marital status. The researchers said the lack of change may reflect the limits of the survey questions, which are broad and may miss subtler effects such as self-esteem, relationship quality or daily functioning.
The paper also fits into a wider and still unsettled debate about what GLP-1 drugs are doing beyond the clinic. Separate research cited by the National Bureau of Economic Research has found clear physical benefits, including better glycemic control and weight loss, while a Danish analysis reported reduced long-term sickness leave but no clear effect on employment or income over four years. Other studies, including work published in JAMA, have pointed to improvements in quality of life and some mental health-related outcomes, underscoring that the evidence is not uniform.
For now, the new analysis does not challenge the established medical case for GLP-1 therapy. It does, however, narrow one argument sometimes made for broader coverage: that the drugs will quickly generate measurable gains in work, marriage or overall well-being. The authors’ results suggest those benefits, if they exist, may be harder to detect, more modest, or limited to different populations than adults with diabetes.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
